Sn

CLINICAL LABORATORIES INDUSTRY Q2 2023 VALUATION UPDATE



# Introduction

We are pleased to share our Clinical Laboratories Multiples Valuation Update for Q2 2023.

At Seale & Associates, we are committed to providing processdriven solutions designed to optimize value and achieve our clients' strategic objectives in a range of transactions including Mergers, Acquisitions, Divestitures and Carve-Outs, Business Sales, Recapitalizations, and Joint Ventures, among other corporate finance and strategy consulting services.

Over the course of 23+ years, we have successfully served clients all over the world, and we are delighted to continue providing investment banking advisory services to our Clinical Laboratories industry clients that are looking to grow through acquisitions or optimize their portfolios through strategic divestitures.

Seale has extensive experience advising leading multinational companies, private equity firms and family-owned businesses across a wide range of industries.

### CLINICAL LABORATORIES Q2 2023





James A. Seale | President jseale@sealeassociates.com



Brett M. Carmel I Senior Managing Director bcarmel@sealeassociates.com



Robert Whitney I Managing Director rwhitney@sealeassociates.com



Sergio Garcia del Bosque I Managing Director sgarcia@sealeassociates.com



Carlos Hernández I Managing Director chernandez@sealeassociates.com



Alejandro Montemayor I Vice President amontemayor@sealeassociates.com

## Small Cap Clinical Laboratories Global Comparable Public Companies

| Company                            |  | Country | Market     | Enterprise<br>Value | Revenue | EBITDA         | Annual Average<br>EV/EBITDA |              | Second Quarter<br>Jun. 30, 2023 |                |
|------------------------------------|--|---------|------------|---------------------|---------|----------------|-----------------------------|--------------|---------------------------------|----------------|
| Company                            |  |         | Cap. US\$M | US\$M               | US\$M   | Margin         | 2021                        | 2022         | EV/<br>EBITDA                   | EV/<br>Revenue |
| Akumin Inc.                        |  | USA     | \$16       | \$1,637             | \$744   | 18.2%          | 10.2x                       | 14.9x        | 8.3x                            | 2.2x           |
| BML, Inc.                          |  | JPN     | \$780      | \$240               | \$1,067 | 16.9%          | 4.0x                        | 1.1x         | 1.1x                            | 0.2x           |
| Capitol Health Limited             | CAPITOLHEALTH  | AUS     | \$191      | \$271               | \$139   | 13.5%          | 11.6x                       | 11.2x        | 12.2x                           | 2.2x           |
| Centro de Imagem Diagnósticos S.A. | alliar méclicos à frente<br>sistema de diagnósticos de saúde | BRA     | \$582      | \$828               | \$235   | 3.2%           | 15.6x                       | 19.5x        | 45.0x                           | 3.6x           |
| FALCO HOLDINGS Co., Ltd.           | <b>FALCO HD</b>  | JPN     | \$147      | \$79                | \$318   | 8.1%           | 3.4x                        | 2.2x         | 2.8x                            | 0.2x           |
| Fleury S.A.                        | fleury medicina<br>e saúde                                   | BRA     | \$1,820    | \$2,324             | \$1,070 | 19.2%          | 10.3x                       | 7.3x         | 9.5x                            | 2.4x           |
| H.U. Group Holdings, Inc.          | HU.GROUP   | JPN     | \$1,083    | \$1,311             | \$1,744 | 13.3%          | 5.9x                        | 3.1x         | 4.6x                            | 0.7x           |
| Healius Limited                    | ı:ı healius  | AUS     | \$1,205    | \$2,345             | \$1,136 | 8.2%           | 10.0x                       | 5.4x         | 8.5x                            | 1.9x           |
| Integral Diagnostics Limited       |  | AUS     | \$509      | \$727               | \$293   | 15.3%          | 15.1x                       | 13.5x        | 14.5x                           | 2.8x           |
| Med Life S.A. 😯 Med I              |  | ROM     | \$512      | \$781               | \$445   | 9.8%           | 10.3x                       | 12.1x        | 13.8x                           | 1.8x           |
| Terveystalo Oyj                    |  | FIN     | \$1,141    | \$1,779             | \$1,391 | 8.6%           | 11.2x                       | 9.0x         | 10.1x                           | 1.3x           |
| Voxel S.A.                         | VOXC   | POL     | \$128      | \$154               | \$107   | 24.8%          | 7.6x                        | 4.4x         | 5.9x                            | 1.5x           |
| Excluded from mean and median      |  |         |            | 3                   |         | Mean<br>Median | 9.1x<br>10.3x               | 7.7x<br>8.2x | 8.3x<br>9.0x                    | 1.6x<br>1.9x   |

## Mid and Large Cap Clinical Laboratories Global Comparable Public Companies

| Company                                    |                          |         | Market     | Enterprise<br>Value | Revenue  | EBITDA         | Annual Average<br>EV/EBITDA |              | Second Quarter<br>Jun. 30, 2023 |                |
|--|--------------------------|---------|------------|---------------------|----------|----------------|-----------------------------|--------------|---------------------------------|----------------|
| Company                                    |                          | Country | Cap. US\$M | US\$M               | US\$M    | Margin         | 2021                        | 2022         | EV/<br>EBITDA                   | EV/<br>Revenue |
| Dian Diagnostics Group Co.,Ltd.            | www.<br>bian diagnostics | CHN     | \$2,209    | \$2,809             | \$2,257  | 13.5%          | 10.8x                       | 7.0x         | 5.4x                            | 1.1x           |
| Eurofins Scientific SE                     | 🛟 eurofins               | LUX     | \$12,243   | \$15,411            | \$7,107  | 17.9%          | 13.7x                       | 9.7x         | 9.5x                            | 2.1x           |
| Laboratory Corporation of America Holdings | labcorp                  | USA     | \$21,382   | \$27,366            | \$14,881 | 15.0%          | 7.0x                        | 7.0x         | 10.6x                           | 1.9x           |
| Medicover AB (publ)                        | MEDICOVER                | SWE     | \$2,271    | \$3,219             | \$1,758  | 9.0%           | 19.5x                       | 12.8x        | 15.9x                           | 2.0x           |
| Quest Diagnostics Incorporated             | Quest<br>Diagnostics     | USA     | \$15,744   | \$20,306            | \$9,488  | 18.5%          | 6.6x                        | 6.6x         | 9.4x                            | 2.1x           |
| RadNet, Inc.                               | RadNet                   | USA     | \$2,187    | \$3,812             | \$1,528  | 12.3%          | 9.6x                        | 8.1x         | 12.3x                           | 2.6x           |
| Sonic Healthcare Limited                   |                          | AUS     | \$11,146   | \$12,787            | \$5,437  | 15.7%          | 10.4x                       | 7.0x         | 8.9x                            | 2.2x           |
| SYNLAB AG SYNLAB                           |                          | DEU     | \$2,171    | \$3,866             | \$3,026  | 6.7%           | 6.5x                        | 4.7x         | 7.6x                            | 1.2x           |
| Excluded from mean and median              |                          |         |            |                     |          | Mean<br>Median | 9.2x<br>10.0x               | 7.8x<br>7.0x | 9.1x<br>9.4x                    | 1.9x<br>2.0x   |


## **Clinical Laboratories – Q2 Global Transactions**

| Date               | Target  | Country     | Description  | Buyer   | Seller   | %<br>Acquired | Size<br>US\$M | EV/<br>EBITDA | EV/<br>Revenue |
|--------------------|---|-------------|--|---|--|---------------|---------------|---------------|----------------|
| Jun-23             | MICROBOLOBIA<br>CALOD FOLSTAL   | CRI         | Provides microbiological testing services and culture media production   |   | -  | ND            | -             | -             | -              |
| Jun-23             | ALLIANCE<br>MR  | USA         | Provides outpatient diagnostic imaging services  | CAPITOL IMAGING                                 | -  | 100.0%        | -             | -             | -              |
| Jun-23             | SYMBION VIP Lab   | IND         | Provides pathology diagnostic services to enable doctors and patients to improve the quality of health outcomes                    | sterling<br>ACCURIS<br>Pathology lab that cares | -  | 100.0%        | -             | -             | -              |
| May-23             |   | USA         | Provides laboratory testing, scientific and technical consulting, clinical research, and institutional review board (IRB) services | MedVenture                                      | -  | 100.0%        | -             | -             | -              |
| May-23             | istituto<br>radiologico<br>"dario gandini".s.r.l.<br>Defense Softens Botas Nicolette Botaster | ITA         | Provides diagnostic imaging services   | affidea   | -  | 100.0%        | -             | -             | -              |
| Apr-23             | Cansford<br>Laboratories<br>Pioneering drug and alcohol testing                               | GBR         | Provides drug, alcohol, and DNA testing services   | GROUP   | -  | 100.0%        | -             | -             | -              |
| Apr-23             |   | DEU         | Provides clinical laboratory services specialized in service provision   | SONIC<br>HEALTHCARE                             | -  | 100.0%        | \$197.6       | -             | 3.6x           |
| Apr-23             | WOMEN'S<br>Ultrasound clinic  | CAN         | Provides various diagnostic ultrasound examinations to women   | canada<br>diagnostic<br>centres                 | -  | 100.0%        | -             | -             | -              |
| Apr-23             | FASTES D'LABS.<br>CLEAN FAST TESTING  | USA         | Provides drug, alcohol, and DNA testing services   | LP First<br>Capital GENESIS PARK                | -  | 100.0%        | -             | -             | -              |
| Apr-23             |   | USA         | Provides infertility treatment options, including IVF, IUI, as well as fertility solutions, such as Egg Freezing and Surrogacy     | FERTILITY                                       | -  | 100.0%        | -             | -             | -              |
| Apr-23             | diagnosticum<br>Labormedizin • Mikrobiologie<br>Pathologie • Humangenetik                     | DEU         | Provides laboratory medicine, microbiology, pathology, and human genetics services   | SONIC<br>HEALTHCARE                             | -  | 100.0%        | \$206.8       | -             | 2.9x           |
| Apr-23             | HYSTACK   | USA         | Develops a ctDNA detection technology that delivers sensitivity and specificity for transformative MRD testing                     | Quest<br>Diagnostics"                           | ALEXANDRIA<br>Venture Investments<br>CATALIO<br>CAPITAL MANAGEMENT | 100.0%        | \$454.0       | -             | -              |
| Jun-23             | Synlab Suisse   | CHE         | Provides medical diagnostic services and specialty testing   | SONIC<br>HEALTHCARE                             | SYNLAB   | 100.0%        | \$167.6       | -             | 1.5x           |
| Apr-23             | C reachbio<br>Research Labs   | USA         | Provides primary cell biology based contract research services and products  |   | -  | 100.0%        | -             | -             | -              |
| <b>Sources:</b> Ca | pital IQ, Merger Marke  | t, Dealogic |  |   |  |               |               | Mean          | 2.7x           |

**Sources:** Capital IQ, Merger Market, Dealogic **ND:** Not Disclosed

Median 2.9x

## **Private Equity Transactions**



#### Source: GF Data

#### **Notes:**

- Data obtained via GF Data, a subscription-based information platform, offering detailed information and metrics about the transactions of Private Equity funds in the U.S. •
- blind approach, the data submitted is less likely to be biased or manipulated.

### CLINICAL LABORATORIES Q2 2023

The data is provided under a blind confidential format. Users of the data are unable to identify the exact company and transaction corresponding to the transaction details. Given this

## Representative Global Engagements



Washington, D.C. | Miami | Cincinnati | Mexico City | Monterrey



## Advisor to Leading **Companies Worldwide**



### CLINICAL LABORATORIES Q2 2023

## Contact









#### Headquarters

901 N. Glebe Road 5<sup>th</sup> Floor Arlington, Virginia +1 (703) 294 6770

### Latin America Office

Av. Javier Barros Sierra 495 3<sup>rd</sup> Floor Park Plaza III Mexico City, Mexico

### **Monterrey Office**

Av. Lázaro Cárdenas 2225 3<sup>rd</sup> Floor San Pedro Garza García, N.L

Please contact us if you would like further information about M&A trends and/or specific transaction multiples for your industry

© Seale & Associates

Washington, D.C. | Miami | Cincinnati | Mexico City | Monterrey

### **Creative Solutions.** Trusted Advice.

For over 20 years, Seale & Associates has served leading public and private companies from around the world and operating in a broad range of industries with a high level of quality, integrity and independence while presenting innovative ideas and trusted solutions to address their most complex dealings.



\$50B+ **CLOSED TRANSACTIONS** GLOBALLY

## **Trusted Advisor to Leading Companies Worldwide**

We have worked repeatedly with many of the most well-known companies in the world...



CLINICAL LABORATORIES Q2 2023

### **SERVICES AND SOLUTIONS**

Mergers & Acquisitions Divestitures Joint Ventures / Alliances Recapitalizations

Due Diligence / Support Expert Witness Testimony **Corporate Finance Advisory** Strategy Consulting

...as well as with reputable funds, family-offices and privately held companies.





# Seale & Associates Creative Solutions. Trusted Advice.

